The dichotomy in the effects of 1,25 dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 on bone γ-carboxyglutamic acid-containing protein in serum and bone in vitamin D-deficient rats

Shlomo Wientroub, Paul A. Price, A Hari Reddi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Vitamin D-deficient, second generation, rachitic rats showed significant decrease in bone Gla protein (BGP) levels in circulation and in the skeleton. 1,25 dehydroxyvitamin D3 (1,25 (OH)2D3) exhibited the most potent influence on serum BGP levels in a dose-dependent manner. At a dose 25 ng/100 g body weight 1,25 (OH)2D3 showed a cumulative effect, i.e., the longer the treatment, the more circulating BGP was detected 24,25 dehydroxyvitamin D3 (24,25(OH)2D3) at the same doses did not show similar effect on the serum BGP levels, regardless of the serum calcium levels. Bone BGP levels assayed at various sites representing endochondral and intramenbranous ossification demonstrated an opposite pattern. 1,25(OH)2D3 administration was not sufficient to restore bone BGP levels to normalcy, whereas in animals treated with 24,25(OH)2D3 bone BGP and calcium levels were significantly higher than control (Vitamin D3-repleted) levels. The present results can be explained by the dual action of 1,25 (OH)2D3 on both synthesis and release of BGP by bone turnover, whereas 24,25 (OH)2D3 stimulates synthesis and accumulation of BGP in bone. These observations imply that caution is required in the interpretation of clinical data based solely on serum BGP determination.

Original languageEnglish (US)
Pages (from-to)166-172
Number of pages7
JournalCalcified Tissue International
Volume40
Issue number3
DOIs
StatePublished - May 1987
Externally publishedYes

Fingerprint

24,25-Dihydroxyvitamin D 3
Calcitriol
Osteocalcin
Vitamin D
Blood Proteins
Bone and Bones
Acids
Calcium
Rickets
Bone Remodeling
Cholecalciferol
Osteogenesis
Skeleton

Keywords

  • 1,25 Dihydroxyvitamin D
  • 24,25 Dihydroxyvitamin D
  • Bone Gla Protein
  • Mineralization
  • Rickets

ASJC Scopus subject areas

  • Endocrinology
  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{d0a1f29b5b9e4715a7bcf8191d7582c7,
title = "The dichotomy in the effects of 1,25 dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 on bone γ-carboxyglutamic acid-containing protein in serum and bone in vitamin D-deficient rats",
abstract = "Vitamin D-deficient, second generation, rachitic rats showed significant decrease in bone Gla protein (BGP) levels in circulation and in the skeleton. 1,25 dehydroxyvitamin D3 (1,25 (OH)2D3) exhibited the most potent influence on serum BGP levels in a dose-dependent manner. At a dose 25 ng/100 g body weight 1,25 (OH)2D3 showed a cumulative effect, i.e., the longer the treatment, the more circulating BGP was detected 24,25 dehydroxyvitamin D3 (24,25(OH)2D3) at the same doses did not show similar effect on the serum BGP levels, regardless of the serum calcium levels. Bone BGP levels assayed at various sites representing endochondral and intramenbranous ossification demonstrated an opposite pattern. 1,25(OH)2D3 administration was not sufficient to restore bone BGP levels to normalcy, whereas in animals treated with 24,25(OH)2D3 bone BGP and calcium levels were significantly higher than control (Vitamin D3-repleted) levels. The present results can be explained by the dual action of 1,25 (OH)2D3 on both synthesis and release of BGP by bone turnover, whereas 24,25 (OH)2D3 stimulates synthesis and accumulation of BGP in bone. These observations imply that caution is required in the interpretation of clinical data based solely on serum BGP determination.",
keywords = "1,25 Dihydroxyvitamin D, 24,25 Dihydroxyvitamin D, Bone Gla Protein, Mineralization, Rickets",
author = "Shlomo Wientroub and Price, {Paul A.} and Reddi, {A Hari}",
year = "1987",
month = "5",
doi = "10.1007/BF02555702",
language = "English (US)",
volume = "40",
pages = "166--172",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - The dichotomy in the effects of 1,25 dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 on bone γ-carboxyglutamic acid-containing protein in serum and bone in vitamin D-deficient rats

AU - Wientroub, Shlomo

AU - Price, Paul A.

AU - Reddi, A Hari

PY - 1987/5

Y1 - 1987/5

N2 - Vitamin D-deficient, second generation, rachitic rats showed significant decrease in bone Gla protein (BGP) levels in circulation and in the skeleton. 1,25 dehydroxyvitamin D3 (1,25 (OH)2D3) exhibited the most potent influence on serum BGP levels in a dose-dependent manner. At a dose 25 ng/100 g body weight 1,25 (OH)2D3 showed a cumulative effect, i.e., the longer the treatment, the more circulating BGP was detected 24,25 dehydroxyvitamin D3 (24,25(OH)2D3) at the same doses did not show similar effect on the serum BGP levels, regardless of the serum calcium levels. Bone BGP levels assayed at various sites representing endochondral and intramenbranous ossification demonstrated an opposite pattern. 1,25(OH)2D3 administration was not sufficient to restore bone BGP levels to normalcy, whereas in animals treated with 24,25(OH)2D3 bone BGP and calcium levels were significantly higher than control (Vitamin D3-repleted) levels. The present results can be explained by the dual action of 1,25 (OH)2D3 on both synthesis and release of BGP by bone turnover, whereas 24,25 (OH)2D3 stimulates synthesis and accumulation of BGP in bone. These observations imply that caution is required in the interpretation of clinical data based solely on serum BGP determination.

AB - Vitamin D-deficient, second generation, rachitic rats showed significant decrease in bone Gla protein (BGP) levels in circulation and in the skeleton. 1,25 dehydroxyvitamin D3 (1,25 (OH)2D3) exhibited the most potent influence on serum BGP levels in a dose-dependent manner. At a dose 25 ng/100 g body weight 1,25 (OH)2D3 showed a cumulative effect, i.e., the longer the treatment, the more circulating BGP was detected 24,25 dehydroxyvitamin D3 (24,25(OH)2D3) at the same doses did not show similar effect on the serum BGP levels, regardless of the serum calcium levels. Bone BGP levels assayed at various sites representing endochondral and intramenbranous ossification demonstrated an opposite pattern. 1,25(OH)2D3 administration was not sufficient to restore bone BGP levels to normalcy, whereas in animals treated with 24,25(OH)2D3 bone BGP and calcium levels were significantly higher than control (Vitamin D3-repleted) levels. The present results can be explained by the dual action of 1,25 (OH)2D3 on both synthesis and release of BGP by bone turnover, whereas 24,25 (OH)2D3 stimulates synthesis and accumulation of BGP in bone. These observations imply that caution is required in the interpretation of clinical data based solely on serum BGP determination.

KW - 1,25 Dihydroxyvitamin D

KW - 24,25 Dihydroxyvitamin D

KW - Bone Gla Protein

KW - Mineralization

KW - Rickets

UR - http://www.scopus.com/inward/record.url?scp=0023156373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023156373&partnerID=8YFLogxK

U2 - 10.1007/BF02555702

DO - 10.1007/BF02555702

M3 - Article

VL - 40

SP - 166

EP - 172

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - 3

ER -